Literature DB >> 14739823

Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII.

Stephan Malherbe1, Ban C H Tsui, Kent Stobart, John Koller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14739823     DOI： 10.1097/00000542-200402000-00038

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  5 in total

Review 1.  [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

Authors:  S A Kozek-Langenecker
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

Review 2.  Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.

Authors:  Marcie J Hursting; Joseph Soffer
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass.

Authors:  Shvetank Agarwal; Beth Ullom; Yasser Al-Baghdadi; Michael Okumura
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-01

4.  Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding.

Authors:  Thomas Klitgaard; Rene Tabanera y Palacios; Kenneth D Boffard; Philip T C Iau; Brian Warren; Sandro Rizoli; Rolf Rossaint; Yoram Kluger; Bruno Riou
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

5.  Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Authors:  Manish J Gandhi; Richard A Pierce; Lini Zhang; Marc R Moon; George J Despotis; Nader Moazami
Journal:  J Cardiothorac Surg       Date:  2007-07-06       Impact factor: 1.637
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.